- Home
- LNZA vs VERU Comparison
LNZA vs VERU Comparison
Compare LNZA & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNZA | VERU |
|---|---|---|
| Founded | 2005 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 39.8M |
| IPO Year | N/A | 1990 |
Fundamental Metrics
Financial Performance| Metric | LNZA | VERU |
|---|---|---|
| Price | $13.09 | $2.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $14.00 | ★ $25.00 |
| AVG Volume (30 Days) | 8.3K | ★ 174.8K |
| Earning Date | 11-19-2025 | 12-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,876,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $113.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.20 | $2.11 |
| 52 Week High | $274.00 | $14.20 |
Technical Indicators
Market Signals| Indicator | LNZA | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 43.86 |
| Support Level | $13.05 | $2.23 |
| Resistance Level | $14.36 | $2.49 |
| Average True Range (ATR) | 1.06 | 0.18 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 6.53 | 37.74 |
Price Performance
Historical ComparisonAbout LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.